Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 10/20 | 0.52 |
| ▸ | HSPD1 | P10809 | 5/20 | 0.52 |
| ▸ | HSPE1 | P61604 | 5/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281116 | 0.92 | PTPN1 (0.62) | MAPTPTPN1PTPN2PTPN5HSPD1 | |
| SCHEMBL4877404 | 0.81 | PTPN2 (0.59) | MAPTTP53LMNAPTPN1PTPN2 | |
| SCHEMBL8278276 | 0.77 | LMNA (0.66) | MAPTTP53LMNAPTPN1PTPN2 | |
| SCHEMBL712861 | 0.76 | L3MBTL1 (0.47) | MAPTTP53PTPN1PTPN2PTPN5 | |
| SCHEMBL3037113 | 0.76 | MAPT (0.56) | MAPTTP53LMNAPTPN1PTPN2 | |
| SCHEMBL8278270 | 0.75 | PFKFB3 (0.51) | MAPTPFKFB3POLB | |
| SCHEMBL4883270 | 0.74 | AKT1 (0.55) | MAPTLMNAPTPN1PTPN2PTPN5 | |
| SCHEMBL8280269 | 0.74 | PFKFB3 (0.53) | PFKFB3 | |
| SCHEMBL8278220 | 0.74 | PGR (0.62) | PFKFB3POLB | |
| SCHEMBL8279518 | 0.73 | PFKFB3 (0.49) | MAPTPTPN1PTPN2PTPN5HSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | MAPT 4739/4885TP53 4112/4885LMNA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.